Literature DB >> 11532281

Autoantibodies to complement components.

L A Trouw1, A Roos, M R Daha.   

Abstract

The complement system is a major component of innate immunity. Under normal conditions the contribution of the complement system is beneficial, but when inappropriately activated it may cause damage to the host and under certain conditions it may even be the target of an autoantibody response. Autoantibodies directed against individual complement components, convertases, complement regulators and complement receptors have been described. The presence of autoantibodies in individuals may be associated with manifestations of disease, but only for some autoantibodies have clear causal relations been described. Autoantibodies against complement components can even be present in healthy individuals, indicating that the development of pathology most likely requires the simultaneous action of multiple processes. Since autoantibodies against complement components may cause depletion of circulating complement levels, leading to a secondary complement deficiency, it is imaginable that this process leads to an increased susceptibility to infections. In the present review, we describe autoantibodies against complement components and their subsequent effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532281     DOI: 10.1016/s0161-5890(01)00043-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  B-cell repertoire specific for an unfolded self-determinant of mouse lysozyme escape tolerance and dominantly participate in the autoantibody response.

Authors:  Yoshiyuki Tsujihata; Yousuke Mizukami; Tadashi Ueda; Takanori So; Taiji Imoto
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 2.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

3.  Anti-C1q autoantibodies in murine lupus nephritis.

Authors:  L A Trouw; M A Seelen; R Visseren; J M G J Duijs; H Benediktsson; E de Heer; A Roos; C van Kooten; M R Daha
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

4.  Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

Authors:  Leendert A Trouw; Tom W L Groeneveld; Marc A Seelen; Jacques M G J Duijs; Ingeborg M Bajema; Frans A Prins; Uday Kishore; David J Salant; J Sjef Verbeek; Cees van Kooten; Mohamed R Daha
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

Review 5.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

6.  Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies.

Authors:  L A Trouw; M A Seelen; J M G J Duijs; H Benediktsson; C Van Kooten; M R Daha
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

7.  Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.

Authors:  Anna Foltyn Zadura; Peter F Zipfel; Maria I Bokarewa; Gunnar Sturfelt; Andreas Jönsen; Sara C Nilsson; Andreas Hillarp; Tore Saxne; Leendert A Trouw; Anna M Blom
Journal:  Arthritis Res Ther       Date:  2012-08-15       Impact factor: 5.156

8.  Anti-C1q autoantibodies, novel tests, and clinical consequences.

Authors:  Michael Mahler; Rosanne A van Schaarenburg; Leendert A Trouw
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.